IDO1 anticorps

N° du produit ABIN1169195

Il existe 4+ publications pour ce produit. L’anticorps anti-IDO1 Polyclonal Lapin est utilisé pour la détection de IDO1 dans des échantillons de Souris. Il a été validé pour WB, ELISA, IHC et ICC.

Aperçu rapide pour IDO1 anticorps (ABIN1169195)

Antigène: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp IDO1 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Détail du produit anti-IDO1 anticorps

Fonction: anti-IDO (mouse), pAb

Specificité: Recognizes mouse IDO1. Detects a band of ~45 kDa by Western blot.

Attributs du produit: Polyclonal Antibody. Recognizes mouse IDO. Detects a band of ~45 kDa by Western blot. Source: Rabbit. Applications: ELISA, ICC, IHC, WB. Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives. IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T-cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T-cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

Stérilité: 0.2 μm filtered

Immunogène: Recombinant mouse IDO1.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 0.2μm-filtered solution in PBS, pH 7.4.

Agent conservateur: Without preservative

Conseil sur la manipulation: After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.

Stock: 4 °C,-20 °C

Stockage commentaire:

+4°C

-20°C

Stable for at least 6 months after receipt when stored at -20°C.

Date de péremption: 6 months

Références pour anticorps anti-IDO1 (ABIN1169195)

Jung, Lee, Chang, Lee, Jeong, Lee, Park, Han, Seo, Lee, Park: "Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 5, pp. 3146-54, (2009) (PubMed).

Yen, Lin, Chen, Huang, Yang, Chang, Lei, Lai: "A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, Issue 2, pp. 641-9, (2009) (PubMed).

Cook, Bickerstaff, Wang, Nadasdy, Della Pelle, Colvin, Orosz: "Spontaneous renal allograft acceptance associated with "regulatory" dendritic cells and IDO." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 180, Issue 5, pp. 3103-12, (2008) (PubMed).

Yadav, Burudi, Alirezaei, Flynn, Watry, Lanigan, Fox: "IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4." dans: Glia, Vol. 55, Issue 13, pp. 1385-96, (2007) (PubMed).

Détails sur IDO1

Antigène: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Autre désignation: IDO

Sujet:

Alternate Names/Synonyms: Indoleamine 2,3-dioxygenase 1, IDO, INDO

Product Description: IDO1 is a heme enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. Cancer cells are able to evade the immune system is by hijacking the checkpoint proteins. Increased IDO1 protein levels drive growth arrest and apoptosis of the effector T cells, a group of immune cells that mediate the immune system's ability to destroy pathogens. By reducing the number of effector T cells, IDO1 overexpression prevents the immune system from effectively destroying cancer cells. IDO1 overexpression has been observed in a wide range of human cancers such as prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head or lung cancer. Physiological IDO1 activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

UniProt: P28776

Pathways: Activated T Cell Proliferation